Electra Therapeutics (NASDAQ:ETRA) Stock Picked Up by Analysts at JPMorgan Chase & Co.

Research analysts at JPMorgan Chase & Co. began coverage on shares of Electra Therapeutics (NASDAQ:ETRA) in a research report issued to clients and investors on Thursday, Briefing.com reports. The firm set an “overweight” rating and a $36.00 price target on the stock. JPMorgan Chase & Co.’s target price points to a potential upside of 297.79% from the company’s current price.

Other research analysts have also recently issued reports about the company. TD Cowen started coverage on Electra Therapeutics in a report on Tuesday, October 13th. They issued a “buy” rating for the company. Zacks Research upgraded Electra Therapeutics to a “hold” rating in a research report on Wednesday, October 14th. Jefferies Financial Group started coverage on shares of Electra Therapeutics in a research report on Tuesday, October 13th. They set a “buy” rating and a $32.00 price objective for the company. Wall Street Zen raised shares of Electra Therapeutics to a “hold” rating in a research report on Saturday, September 26th. Finally, Evercore assumed coverage on Electra Therapeutics in a research note on Tuesday, October 13th. They issued an “outperform” rating and a $36.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, Electra Therapeutics has an average rating of “Buy” and a consensus target price of $34.67.

Electra Therapeutics Trading Up 2.7%

NASDAQ:ETRA opened at $9.05 on Thursday. Electra Therapeutics has a 12-month low of $8.50 and a 12-month high of $15.50.

Insider Activity

In other Electra Therapeutics news, Director Carl L. Gordon purchased 1,333,333 shares of the stock in a transaction that occurred on Monday, September 21st. The shares were acquired at an average cost of $15.00 per share, with a total value of $19,999,995.00. Following the completion of the transaction, the director owned 5,126,891 shares in the company, valued at $76,903,365. The trade was a 35.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Orbimed Advisors Llc bought 1,333,333 shares of the firm’s stock in a transaction on Monday, September 21st. The shares were acquired at an average price of $15.00 per share, for a total transaction of $19,999,995.00. Following the transaction, the director owned 5,126,891 shares in the company, valued at approximately $76,903,365. This represents a 35.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Electra Therapeutics Company Profile

Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. The company’s research is directed toward selectively influencing immune-cell activity to address serious diseases, including cancer and autoimmune conditions.

Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell modulation approach. Its programs are intended to improve the body’s ability to recognize, control, or eliminate disease-associated cells while limiting effects on healthy tissue.